NCT02990546

Midodrine in the Recovery Phase of Septic Shock

Midodrine Use in the Recovery Phase of Septic Shock

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Virginia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

Detailed description

The investigators aim to investigate the use of midodrine in the recovery phase of septic shock in a randomized control trial. The investigators hypothesize that midodrine use initiated after stabilization or improving intravenous vasopressor requirement will lead to decreased length of ICU stay and length of time that intravenous vasopressors are required. The investigators plan to enroll and consent patients at the onset of septic shock. Once IV vasopressor requirement is stabilized or decreasing, males and females will be randomized in 1:1 fashion to receive either standard clinical care or standard clinical care plus oral midodrine. The investigators will analyze length of stay in the ICU, time on vasopressors, time needing a central line, and hospital length of stay.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	midodrine	Midodrine will be given to treatment arm as enteral medication
OTHER	Standard of Care	Patients in the control arm will receive standard of care for septic shock

Timeline

• Start date: 2017-03-01
• Primary completion: 2018-05-02
• Completion: 2018-05-02
• First posted: 2016-12-13
• Last updated: 2024-01-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study